Literature DB >> 23860929

Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast.

Aram S A van Brussel1, Arthur Adams, Jeroen F Vermeulen, Sabrina Oliveira, Elsken van der Wall, Willem P Th M Mali, Paul J van Diest, Paul M P van Bergen En Henegouwen.   

Abstract

Ductal carcinoma in situ (DCIS) of the breast is difficult to remove completely during surgery as it is not palpable and can therefore require re-excision. Real-time visualization of DCIS using near-infrared fluorescent probes could help the surgeon during surgery as well as the pathologist post-operatively to distinguish the tumor from healthy tissue. As hypoxia-induced necrosis is a common phenomenon in DCIS, we investigated the molecular imaging of DCIS using a fluorescent antibody targeting a hypoxia marker, carbonic anhydrase IX (CAIX), in a preclinical mouse model. A monoclonal antibody against human CAIX was fluorescently labeled with the near-infrared dye IRDye800CW and characterized in vitro. An in vivo study was performed in SCID/Beige mice that were orthotopically transplanted with human breast cancer cells mimicking human DCIS (MCF10DCIS) and MCF10DCIS stably expressing CAIX. A clinically approved fluorescence imaging system was used to monitor probe uptake and to determine tumor-to-normal tissue ratios (TNR). Mean in vivo TNR of CAIX-transduced (CAIX+) tumors was 7.5 ± 0.5. Mean in vivo TNR of DCIS tumors with hypoxic areas reached a plateau level at 48 h after injection of 2.1 ± 0.1 (mean ± SEM) compared to 1.7 ± 0.1 in DCIS without hypoxic areas. Mean intra-operative TNR of DCIS tumors with necrotic regions was higher than that of DCIS tumors without necrotic regions 96 h after injection-2.9 ± 0.1 and 1.5 ± 0.1, respectively-while the TNR of CAIX+ tumors was 11.2 ± 1.0. Specific tumor uptake of MabCAIX-IRDye800CW was confirmed by a biodistribution assay, and immunofluorescence imaging on tumor sections showed specific uptake in hypoxic tumor regions, with higher contrast than conventional chromagen-based immunohistochemistry. Molecular fluorescence imaging with MabCAIX-IRDye800CW can be successfully used to detect hypoxic DCIS before and during surgery to facilitate radical resection. Furthermore, it allows for sensitive CAIX-specific immunofluorescence microscopy of tumor sections, thereby introducing the concept of molecular fluorescence pathology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860929     DOI: 10.1007/s10549-013-2635-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  15 in total

1.  Vision 20/20: Molecular-guided surgical oncology based upon tumor metabolism or immunologic phenotype: Technological pathways for point of care imaging and intervention.

Authors:  Brian W Pogue; Keith D Paulsen; Kimberley S Samkoe; Jonathan T Elliott; Tayyaba Hasan; Theresa V Strong; Daniel R Draney; Joachim Feldwisch
Journal:  Med Phys       Date:  2016-06       Impact factor: 4.071

Review 2.  Advances in fluorescent-image guided surgery.

Authors:  Mark J Landau; Daniel J Gould; Ketan M Patel
Journal:  Ann Transl Med       Date:  2016-10

3.  Development of a Non-invasive Assessment of Hypoxia and Neovascularization with Magnetic Resonance Imaging in Benign and Malignant Breast Tumors: Initial Results.

Authors:  Andreas Stadlbauer; Max Zimmermann; Barbara Bennani-Baiti; Thomas H Helbich; Pascal Baltzer; Paola Clauser; Panagiotis Kapetas; Zsuzsanna Bago-Horvath; Katja Pinker
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

4.  High resolution 3D MRI of mouse mammary glands with intra-ductal injection of contrast media.

Authors:  Erica Markiewicz; Xiaobing Fan; Devkumar Mustafi; Marta Zamora; Brian B Roman; Sanaz A Jansen; Kay Macleod; Suzanne D Conzen; Gregory S Karczmar
Journal:  Magn Reson Imaging       Date:  2014-08-29       Impact factor: 2.546

5.  Increased precision of orthotopic and metastatic breast cancer surgery guided by matrix metalloproteinase-activatable near-infrared fluorescence probes.

Authors:  Chongwei Chi; Qian Zhang; Yamin Mao; Deqiang Kou; Jingdan Qiu; Jinzuo Ye; Jiandong Wang; Zhongliang Wang; Yang Du; Jie Tian
Journal:  Sci Rep       Date:  2015-09-23       Impact factor: 4.379

6.  Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases.

Authors:  Laura S Jiwa; Paul J van Diest; Laurien D Hoefnagel; Jelle Wesseling; Pieter Wesseling; Cathy B Moelans
Journal:  BMC Cancer       Date:  2014-11-22       Impact factor: 4.430

7.  Optical imaging of pre-invasive breast cancer with a combination of VHHs targeting CAIX and HER2 increases contrast and facilitates tumour characterization.

Authors:  Marta M Kijanka; Aram S A van Brussel; Elsken van der Wall; Willem P T M Mali; Paul J van Diest; Paul M P van Bergen En Henegouwen; Sabrina Oliveira
Journal:  EJNMMI Res       Date:  2016-02-10       Impact factor: 3.138

8.  Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer.

Authors:  Aram S A van Brussel; Arthur Adams; Sabrina Oliveira; Bram Dorresteijn; Mohamed El Khattabi; Jeroen F Vermeulen; Elsken van der Wall; Willem P Th M Mali; Patrick W B Derksen; Paul J van Diest; Paul M P van Bergen En Henegouwen
Journal:  Mol Imaging Biol       Date:  2016-08       Impact factor: 3.488

Review 9.  Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins.

Authors:  Martin C Boonstra; Susanna W L de Geus; Hendrica A J M Prevoo; Lukas J A C Hawinkels; Cornelis J H van de Velde; Peter J K Kuppen; Alexander L Vahrmeijer; Cornelis F M Sier
Journal:  Biomark Cancer       Date:  2016-09-27

Review 10.  Stromal Targets for Fluorescent-Guided Oncologic Surgery.

Authors:  Martin C Boonstra; Jai Prakash; Cornelis J H Van De Velde; Wilma E Mesker; Peter J K Kuppen; Alexander L Vahrmeijer; Cornelis F M Sier
Journal:  Front Oncol       Date:  2015-11-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.